Skip to content

Trial · Observational

RecruitingPhase not statedRegistry data

GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes

Short name GLP1-SARCO

NCTNCT07858864 (opens ClinicalTrials.gov in a new tab)Other idKAEWZ026.06.227
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Recruiting
Phase
Phase not stated
Enrollment
42 participants (estimated)
Sponsor
Istanbul Saglik Bilimleri University · Other
Design
Not stated
Countries
1 country

Turkey (Türkiye)

Start
30 May 2026
Primary completion
30 Nov 2026 (estimated)
Completion
30 Nov 2026 (estimated)
First posted
5 Oct 2026
Last update posted
8 Oct 2026
Conditions
Obesity · Sarcopenia

Timeline

1 trial · 1 ongoing

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20262027
  1. Ph –

    GLP1-SARCO

    NCT07858864

    30 May 2026 to est. 30 Nov 2026

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists such as semaglutide and tirzepatide produce marked weight loss in people with obesity, with reported reductions of about 15-20%. Rapid weight loss may reduce not only fat mass but also lean body mass and skeletal muscle mass, raising concern about sarcopenia and sarcopenic obesity. Evidence in non-diabetic obese individuals is limited and inconsistent. This prospective descriptive study will assess muscle mass, muscle strength, physical performance and sarcopenia risk in non-diabetic obese adults starting GLP-1 RA therapy, at baseline and at month 3, and will examine how weight loss relates to changes in body composition.

Interventions

  • GLP-1 receptor agonist (e.g., semaglutide, tirzepatide) - prescribed by the treating physician as standard care; the study does not assign or alter treatment.Drug

Arms1

  • Other

    Non-diabetic obese adults receiving a GLP-1 RA (or GLP-1/GIP dual agonist) for obesity

    Adults (≥18 years) with BMI ≥30 kg/m² and no diabetes who start GLP-1 RA treatment under routine clinical care and are followed at the Diabetes Education Unit.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Change in SARC-F (Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls) total score

    Time frame · Baseline (GLP-1 RA initiation) and 3 months

    Registry description

    SARC-F is a 5-item sarcopenia screening questionnaire. Total score ranges from 0 to 10, and higher scores indicate a worse outcome (greater risk of sarcopenia). Change = month 3 score minus baseline score, reported in points on the scale.

Secondary outcomes(1)

  1. Number of participants with a positive SARC-F screening result

    Time frame · Baseline and 3 months

    Registry description

    Positive screening is defined as a SARC-F total score of 4 or higher (scale range 0 to 10; higher scores indicate a worse outcome). Reported as number of participants.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies2

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2023

3 results

Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.

Silver et al. 2023Diabetes, obesity & metabolismcited by 77

PMID 37188932PMC10544709DOI 10.1111/dom.15113PUB-37188932

Rights unknown3 results
Source linkSee results (3)

More studies

1 study on this page

PubMed tag: none · 2023

Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.

Aroda et al. 2023Diabetes, obesity & metabolismcited by 40

PMID 36700417DOI 10.1111/dom.14990PUB-36700417

Full text at the publisher
Publisher page

Other registry references

References listed at the registry that are not in PepBank. They link to PubMed.

  • ResultDamluji AA, Alfaraidhy M, AlHajri N, Rohant NN, Kumar M, Al Malouf C, Bahrainy S, Ji Kwak M, Batchelor WB, Forman DE, Rich MW, Kirkpatrick J, Krishnaswami A, Alexander KP, Gerstenblith G, Cawthon P, deFilippi CR, Goyal P. Sarcopenia and Cardiovascular Diseases. Circulation. 2023 May 16;147(20):1534-1553. doi: 10.1161/CIRCULATIONAHA.123.064071. Epub 2023 May 15. PMID 37186680

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Age 18 years or older * Diagnosis of obesity (BMI \>30 kg/m²) * Currently using a GLP-1 RA * No hearing, speech or cognitive impairment * Not receiving treatment for major depressive disorder and not using antidepressants * Verbal consent to participate Exclusion Criteria: * Diagnosis of diabetes * History of chronic kidney failure, chronic liver disease, decompensated heart failure or malignancy * Pregnancy or breastfeeding * Walking impairment * Not meeting inclusion criteria or unwilling to participate

PepBank is a research reference. Talk to a doctor before you use any peptide.